@article{3102826,
    title = "Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes",
    author = "Liapis, K. and Papadopoulos, V. and Vrachiolias, G. and Galanopoulos, A.G. and Papoutselis, M. and Papageorgiou, S.G. and Diamantopoulos, P.T. and Pappa, V. and Viniou, N.-A. and Kourakli, A. and Τsokanas, D. and Vassilakopoulos, T.P. and Hatzimichael, E. and Bouronikou, E. and Ximeri, M. and Pontikoglou, C. and Megalakaki, A. and Zikos, P. and Panayiotidis, P. and Dimou, M. and Karakatsanis, S. and Papaioannou, M. and Vardi, A. and Kontopidou, F. and Harchalakis, N. and Adamopoulos, I. and Symeonidis, A. and Kotsianidis, I.",
    journal = "Blood cancer journal",
    year = "2021",
    volume = "11",
    number = "2",
    publisher = "Springer Nature BV",
    doi = "10.1038/s41408-021-00424-4",
    keywords = "azacitidine;  beta 2 microglobulin;  antineoplastic antimetabolite;  azacitidine, aged;  assessment of humans;  blast cell;  blood transfusion;  bone marrow cell;  cancer prognosis;  cancer specific survival;  cytogenetics;  drug efficacy;  Endothelial Activation and Stress Index;  estimated glomerular filtration rate;  female;  high risk patient;  human;  intermediate risk patient;  International Prognostic Scoring System;  Letter;  low risk patient;  major clinical study;  male;  myelodysplastic syndrome;  overall survival;  risk factor;  adult;  follow up;  middle aged;  myelodysplastic syndrome;  prognosis;  survival analysis;  very elderly, Adult;  Aged;  Aged, 80 and over;  Antimetabolites, Antineoplastic;  Azacitidine;  Female;  Follow-Up Studies;  Humans;  Male;  Middle Aged;  Myelodysplastic Syndromes;  Prognosis;  Risk Factors;  Survival Analysis"
}